D
Daniel R. Marshak
Researcher at Osiris Therapeutics, Inc.
Publications - 31
Citations - 22839
Daniel R. Marshak is an academic researcher from Osiris Therapeutics, Inc.. The author has contributed to research in topics: Mesenchymal stem cell & Stem cell. The author has an hindex of 19, co-authored 31 publications receiving 21881 citations. Previous affiliations of Daniel R. Marshak include Case Western Reserve University & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Multilineage Potential of Adult Human Mesenchymal Stem Cells
Mark F. Pittenger,Alastair Morgan Mackay,Stephen C. Beck,Rama K. Jaiswal,Robin Douglas,Joseph D. Mosca,Mark Aaron Moorman,Donald William Jr. Ward Road Simonetti,Stewart Craig,Daniel R. Marshak +9 more
TL;DR: Adult stem cells isolated from marrow aspirates of volunteer donors could be induced to differentiate exclusively into the adipocytic, chondrocytic, or osteocytic lineages.
Journal ArticleDOI
Adult Human Mesenchymal Stem Cell Differentiation to the Osteogenic or Adipogenic Lineage Is Regulated by Mitogen-activated Protein Kinase
Rama K. Jaiswal,Neelam Jaiswal,Scott P. Bruder,Gabriel Mbalaviele,Daniel R. Marshak,Mark F. Pittenger +5 more
TL;DR: Observations provide a potential mechanism involving MAP kinase activation in osteogenic differentiation of adult stem cells and suggest that commitment of hMSCs into osteogenic or adipogenic lineages is governed by activation or inhibition of ERK, respectively.
Book
Stem Cell Biology
TL;DR: This volume, which features contributions from many of the world's leading laboratories, provides a broad and authoritative basis for understanding the biology of stem cells and the excitement about their potential for clinical exploitation.
Patent
Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
James S. Burns,Daniel R. Marshak +1 more
TL;DR: In this paper, an inhalation device is provided with a control mechanism consisting of a controller, a timer, an actuator, and a signalling device, which is used to assure patient compliance with a drug dosage regimen.
Patent
Uses for non-autologous mesenchymal stem cells
TL;DR: Methods and devices using non-autologous mesenchymal stem cells comprising treating a recipient in need of the stem cells with an effective amount of mesenchymycous stem cells, including methods and preparations for treating and regenerating connective tissue and enhancing bone marrow engraftment in an individual as mentioned in this paper.